Oncogenic challenge of bromocriptine and L-arginine versus conventional antidiabetics on diethyl nitrosamine-induced liver tumorigenesis in diabetic rats: focus on AMPK activation

Wafaa A. Hewedy; Eman I. Anwar; Gehan M. Sharara; Mona A. Hadi; Suzan A. Darwish; Cherine A. Ismail

doi:10.18203/2319-2003.ijbcp20223348

Authors

Wafaa A. Hewedy Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria, Egypt http://orcid.org/0000-0002-8287-4179
Eman I. Anwar Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Gehan M. Sharara Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Mona A. Hadi Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Suzan A. Darwish Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Cherine A. Ismail Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20223348

Keywords:

Hepatocellular carcinoma, Insulin, Metformin, T2DM

Abstract

Background: Diabetes mellitus (DM) is associated with a spectrum of cancers where the metabolic antecedents, consequences, and therapy might affect cancer risk. The association between hepatocellular carcinoma (HCC) and DM had been confirmed. Approaches to HCC prevention focus on the molecular regulators of the disease process defined as the inflammation-fibrosis-cancer axis. The AMP-activated protein kinase (AMPK) is an interesting metabolic tumor suppressor and a promising target for cancer prevention and therapy. This study aimed to investigate the effects of bromocriptine mesylate and L-arginine on hepatic carcinogenesis on a rat model of hepatic neoplasia induced by diethyl nitrosamine (DENA) and promoted by type-2 DM in contrast to the conventional antidiabetics.

Methods: One hundred male Wistar rats were randomly assigned into two sets; control set (normal, HCC, DM, and combined HCC/DM) and treated set where rats received one of the following drugs for another 5 weeks: insulin glargine, glimepiride, metformin, pioglitazone, bromocriptine mesylate, or L-arginine. Bodyweight changes, blood glucose level, liver functions tests, serum C-peptide and alpha-fetoprotein (AFP), and hepatic activated AMPK were assessed beside the hepatic histopathological changes.

Results: Equivalent to metformin, bromocriptine and L-arginine treatment significantly reduced AFP, despite their minor glycemic control. L-arginine induced AMPK activation, yet less than metformin. Histopathologic examination revealed a reduction in hepatic intra-lobular chronic inflammatory cell infiltration, steatosis and necrosis by metformin, bromocriptine, and L-arginine. Hepatic necro-inflammatory changes were most prominent in insulin-treated rats.

Conclusions: L-arginine and bromocriptine mesylate prevent early neoplastic changes almost equivalent to metformin at least partially via hepatic AMPK activation.

Metrics

Metrics Loading ...

References

Sun G, Kashyap SR. Cancer risk in type 2 diabetes mellitus: Metabolic links and therapeutic considerations. J Nutr Metab. 2011.

Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ, Yan SL. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2014;9(5):23-9.

Yang XL. Diabetes, insulin and cancer risk. World J Diab. 2012;3(4):60.

Guillot A, Tacke F. Liver Macrophages: Old Dogmas and New Insights. Hepatol Commun. 2019;3(6):730-43.

Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol. 2019;18(1):1-15.

Ding YF, Wu ZH, Wei YJ, Shu L, Peng YR. Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine. J Cancer Res Clin Oncol. 2017;143(5):821-34.

Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: Control of metabolism and cell growth. Future Oncol. 2010;6(3):457-70.

Zhang BB, Zhou G, Li C. AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome. Cell Metab. 2009;9(5):407-16.

Holczer M, Hajdú B, Lőrincz T, Szarka A, Bánhegyi G, Kapuy O. A double negative feedback loop between MTORC1 and AMPK kinases guarantees precise autophagy induction upon cellular stress. Int J Mol Sci. 2019;20(22):23-9.

Holczer M, Hajdú B, Lőrincz T, Szarka A, Bánhegyi G, Kapuy O. Fine-tuning of AMPK–ULK1–mTORC1 regulatory triangle is crucial for autophagy oscillation. Sci Rep. 2020;10(1):1-12.

Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta Proteins Proteom. 2010;1804(3):581-91.

Hagberg KW, Mcglynn KA, Sahasrabuddhe VV, Jick S. Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer. 2014;111(9):1710-7.

Holt RIG, Barnett AH, Bailey CJ. Bromocriptine: Old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12(12):1048-57.

Tavares G, Marques D, Barra C, Rosendo-Silva A, Costa T, Rodrigues P, et al. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes. Mol Metab. 2021;51(4):101.

de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010;79(12):1827-36.

Krause MS, Mcclenaghan NH, Flatt PR, de Bittencourt PIH, Murphy C, Newsholme P. L-Arginine is essential for pancreatic β-cell functional integrity, metabolism and defense from inflammatory challenge. J Endocrinol. 2011;211(1):87-97.

Altabas V. Diabetes, endothelial dysfunction, and vascular repair: What should a diabetologist keep his eye on? Int J Endocrinol. 2015.

Abdel-Hamid NM, Nazmy MH, Abdel-Bakey AI. Polyol profile as an early diagnostic and prognostic marker in natural product chemoprevention of hepatocellular carcinoma in diabetic rats. Diabetes Res Clin Pract. 2011;92(2):228-37.

Weykamp C. HbA1c: A review of analytical and clinical aspects. Ann Lab Med. 2013;33(6):393-400.

Sanghavin NM, Jivani NG. A colorimetric method for the determination of nitrazepam. Talanta. 1979;26(1):63-4.

Belfield A, Goldberg DM. Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme. 1971;12(5):561-73.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75.

Llovet JM, Kelley RK, Villanueva A, Singal A, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):23-9.

Eferl R, Casanova E. Mouse models of cancer: methods and protocols. Mouse Mod Cancer Met Prot. 2015;1267:1-456.

Bertrand L, Ginion A, Beauloye C, Hebert A, Guigas B, Hue L, Vanoverschelde J. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol. 2006;291(1):239-50.

Yang YM, Han CY, Kim YJ, Kim SG. AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability. World J Gastroenterol. 2010;16(30):3731-42.

Shah SZA, Zhao D, Hussain T, Yang L. Role of the AMPK pathway in promoting autophagic flux via modulating mitochondrial dynamics in neurodegenerative diseases: Insight into prion diseases. Ageing Res Rev. 2017;40(9):51-63.

Caligiuri A, Bertolani C, Guerra CT, Aleffi S, Galastri S, Trappoliere M, et al. Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology. 2008;47(2):668-76.

Jung UJ, Choi MS. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184-223.

Alvino CL, Ong SC, McNeil KA, Delaine C, Booker G, Wallace J, et al. Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. PLoS One. 2011;6(11):23-9.

Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(7):1170-5.

Pasello G, Urso L, Conte P, Favaretto A. Effects of sulfonylureas on tumor growth: a review of the literature. Oncol. 2013;18(10):1118-25.

Huang X, Jan LY. Targeting potassium channels in cancer. J Cell Biol. 2014;206(2):151-62.

Lamoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77-96.

Salmond RJ. mTOR regulation of glycolytic metabolism in T cells. Front Cell Dev Biol. 2018;6(9):1-9.

Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025-78.

Gaziano JM, Cincotta AH, O’Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diab Care. 2010;33(7):1503-8.

Pijl H, De Leeuw Van Weenen JE, Parlevliet ET, Schrder-Van Der Elst JP, Van Den Berg SA, Willems Van Dijk K, et al. Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. Exp Diab Res. 2011.

Srivastava RAK, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: An emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53(12):2490-514.

Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 2013;123(7):2764-72.

De Castro Barbosa T, Jiang LQ, Zierath JR, Nunes MT. L-Arginine enhances glucose and lipid metabolism in rat L6 myotubes via the NO/ c-GMP pathway. Metabolism. 2013;62(1):79-89.

Mohan S, Patel H, Bolinaga J, Soekamto N. AMP-activated protein kinase regulates L-arginine mediated cellular responses. Nutr Metab. 2013;10(1):16-23.